In the absence of direct evidence between SGLT2 inhibitors and finerenone, this study, for the first time, provided the estimators of the relative efficacy of SGLT2 inhibitors versus finerenone on renal and cardiovascular outcomes in patients with concomitant T2D and CKD by network meta-analysis incorporating large trials of gliflozins versus placebo and those of finerenone versus placebo. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.